Generate Biomedicines盘中因旧Q2业务更新转述上涨，核心事实已于8月6日披露

Generate Biomedicines Inc. (GENB), a clinical-stage generative biology company, recently reported second-quarter 2026 financial results and provided updates across its clinical pipeline and strategic collaborations.
Revenue for the second quarter was $6.3 million, compared with $10.1 million in the prior-year quarter.
Research and development expenses increased to $64.3 million from $59.7 million, primarily reflecting continued investment in the Phase 3 SOLAIRIA trials of GB-0895 in severe asthma.
General and administrative expenses rose to $13.6 million from $10.5 million, driven primarily by higher stock-based compensation.
Net loss widened to $67.3 million, or approximately $0.52 per share, compared with a net loss of $56.7 million, or $1.94 per share, in the prior-year quarter.
Cash, cash equivalents and marketable securities totalled approximately $457.4 million as of June 30, 2026.
Generate expects its existing liquidity to fund its current operating plan into the first half of 2028.
On the clinical front, Generate continues to advance GB-0895, an investigational anti-TSLP monoclonal antibody, in severe asthma and COPD.
The global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials in severe asthma are recruiting across six global regions.
The studies have received regulatory approvals in 33 countries as part of a planned 42-country development program.
Generate also plans to present Phase 1b data for GB-0895 in COPD at the European Respiratory Society Congress in September.
In oncology, all patients in the first cohort of the Phase 1 study evaluating GB-4362, an MMAE neutralizer designed to reduce treatment-limiting toxicities associated with antibody-drug conjugates, have been enrolled and initially dosed.
GB-4362 has received FDA Fast Track designation for the prevention and/or reduction of enfortumab vedotin-induced toxicity in patients with urothelial cancer.
Generate also said Novartis has advanced a biologic designed using its AI-enabled Generate Platform into its preclinical pipeline, marking the first time a biologic engineered using the platform has reached this stage.
Separately, the Phase 1 study of GB-5267, an IL-18-armored MUC16 CAR T therapy being developed with Roswell Park Comprehensive Cancer Center for advanced platinum-resistant ovarian cancer, is now recruiting, with first dosing expected in 2026.
GENB shares are currently trading at $21.07, up 19.02%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.